Keros Therapeutics, Inc.KROSNASDAQ
Loading
R&D Expenses Over TimeContracting
Percentile Rank71
3Y CAGR+14.1%
5Y CAGR+30.8%
Year-over-Year Change
Research and development spending
3Y CAGR
+14.1%/yr
vs +71.4%/yr prior
5Y CAGR
+30.8%/yr
Recent deceleration
Acceleration
-57.3pp
Decelerating
Percentile
P71
Within normal range
vs 5Y Ago
3.8x
Strong expansion
Streak
1 yr
Consecutive declineContracting
| Period | Value | YoY Change |
|---|---|---|
| 2025 | $129.64M | -25.3% |
| 2024 | $173.63M | +28.4% |
| 2023 | $135.26M | +55.0% |
| 2022 | $87.27M | +58.3% |
| 2021 | $55.14M | +62.9% |
| 2020 | $33.86M | +94.8% |
| 2019 | $17.38M | +71.9% |
| 2018 | $10.11M | - |